A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus
placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine
dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36
enrolled. Primary outcome is methamphetamine absitience over the 10 week treatment period,
and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urine
positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period.
Secondary measures include treatment retention, drug craving, mood, and safety.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health